CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC announced two key hires for its executive management team. Bruce A. Silver, MD, FACP, as Chief Medical Officer will lead Tau’s clinical development and research program centered on mibefradil and its novel Interlaced Therapy™ approach. Paul H. Sartori, PhD, MBA, will fill the new position of Vice President of Operations and Strategy. Both will be integral to the company’s mission of developing T-type calcium channel inhibitors for treating solid tumors.
Dr. Silver has extensive experience in oncology with large and small pharmaceutical companies, most recently developing and executing the clinical programs for Avila Therapeutics (acquired by Celgene). Dr. Sartori has served as a business advisor to Tau since 2008 and brings 30 years of business experience and organizational development expertise from senior positions at large pharmaceutical companies.
“Bringing on these two experienced professionals signals our focus on executing our clinical trials and strategically building the organization,” said Andrew J. Krouse, President and CEO of Tau Therapeutics. “Our clinical development program in oncology and the appropriate growth and planning for our company are the keys to success at this stage. We are proud that people of this caliber have joined our team.”
Bruce A. Silver, MD, FACP, has twenty years of full-time clinical oncology practice experience. Dr. Silver then served at PRA International as Vice President of Global Product Development where he was intensively involved in providing oncology drug development consultative services to numerous biotechnology and pharmaceutical clients. He was instrumental in the clinical development of several oncology therapeutics including Avastin®, Nexavar®, Tarceva®, and Velcade®. Most recently Dr. Silver developed and executed the clinical programs for Avila Therapeutics (acquired by Celgene) and Adnexus Therapeutics (acquired by Bristol Myers Squibb).
Paul Sartori, PhD, MBA, has over thirty years executive experience in big pharma and start-up companies. Dr. Sartori joins Tau Therapeutics from Parexel International where he held the position of Vice President of Human Resources. He previously served as Corporate Vice President of Public Affairs and Human Resources at Bausch & Lomb, Senior Vice President of Organizational Development and Human Resources for BioTrove, Inc. (acquired by Life Technologies), Global Vice President of Human Resources at CIBA-Corning Diagnostics, Senior Vice President of HR and Communications at CIBA-Geigy, and Executive Vice-President, External Affairs and Human Resources at Novartis.
About Tau Therapeutics LLC
Tau Therapeutics, a privately held oncology company based in Charlottesville, VA, is at the forefront of cancer research focusing on controlling the proliferation pathway. Tau’s Interlaced Therapy™ is built on the rationale that using a T-type calcium channel inhibitor to increase the proportion of cancer cells and cancer stem cells at the point of maximum metabolic vulnerability in S phase will increase cell death caused by cytotoxic chemotherapies. By more effectively reducing tumor burden and killing the cells that cause recurrence, Tau believes it will offer a significant advancement in the treatment of cancer.
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.